SOURCE: UV Flu Technologies, Inc.
CENTERVILLE, MA–(Marketwire – June 25, 2010) – UV Flu Technologies, Inc. (
The Seagate Hotel and Spa in Delray Beach, Florida, and the Boston Harbor Hotel, in Boston, MA are both now able to visibly ensure their clients’ health is clearly positioned as a major consideration with the introduction of the ViraTech UV-400 air purification product. This innovative apparatus has been patented and FDA cleared as a medical device and is considered to be an important step forward in providing virtually any public property with the ability to responsibly enhance air quality simply, easily, effectively and visibly.
“The ViraTech UV-400 was the perfect match, and completion to our luxury destination spa,” said William Sander, General Manager of the Seagate Hotel. “We were excited about ordering these air purifiers for our hotel. These products actually kill bacteria, providing extra protection to our guests, which is very important to us at the Seagate. Healthy guests have a positive experience about their stay, which makes them want to come back. Providing this extra level of protection also sets us apart from the competition.”
“The Boston Harbor Hotel always puts their customers’ health first,” stated Bill Fegley, President of Puravair. “This property provides rooms for many visitors to the city undergoing medical treatments in local hospitals, and hotel management had the pro-active foresight to introduce our air purifiers to these customers, particularly those undergoing cancer treatments. We believe this particular market, which exists across the country at thousands of hotel properties that are located adjacent to health centers, is potentially immense, and offers a real plus to property managers as a health conscious marketing vehicle that shows they truly care about their customers’ and families’ experiences at a time in their lives when extra touches can mean the most.”
“Hotels, hospitals, and medical waiting rooms are all a potentially huge market for our products,” said John Lennon, President of UV Flu Technologies. “Our technology is unique, and to that end, we recently undertook a re-branding of our devices from ViraGuard, to ViraTech, in order to better underscore the importance of technological advancement in all our products. The ViraTech UV-400 is one of the few Indoor Air Quality (‘IAQ’) products in the world cleared by the FDA for use as a medical device, and is designed specifically to kill over 99% of bacteria with each pass, and we believe that with all of the recent media discussion on air quality, that there is huge potential and need for this superior, maintenance-free and highly effective product.”
Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
About UV Flu Technologies, Inc. (
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO